News
More superbugs, fewer drugs. How can pharma companies ensure the handful of promising antimicrobials make it to the frontlines of drug resistance?
23 May 2024
Date
10 September 2024
A new report from the Access to Medicine Foundation reveals how patient-focused pharma companies' access efforts are
Morningstar covers the Access to Medicine Foundation’s latest report on the critical issue of how some of the largest pharma companies are reaching patients worldwide, especially in low- and middle-income countries (LMICs)
Direct links
The article details the Access to Medicine Foundation's latest report, which evaluates the patient reach commitments and measurement methods of major pharmaceutical companies.
The article outlines the report's findings, which identified 42 unique approaches for measuring patient reach. Notably,19 of the 20 assessed companies reported using approaches to track the patients they reach with essential medicines in low- and middle-income countries (LMICs). It also highlights the potential for companies to refine their commitments and improve their efforts to assist those in need.
“We have seen that the pharmaceutical industry is making ambitious commitments to reach more patients worldwide,” the article quotes Jayasree K. Iyer, CEO of the Foundation. “However, this report reveals that there is still much work to be done in achieving meaningful impact and calls for urgent steps to ensure lifesaving products reach every patient, everywhere.”
